Cliff Asness's GLUE Position Overview
Cliff Asness (via Aqr Capital Management LLC) currently holds 785,057 shares of Monte Rosa Therapeutics, Inc. (GLUE) worth $12.31 M, representing 0.01% of the portfolio. First purchased in 2025-Q1, this short-term holding has been held for 4 quarters.
Based on 13F filings, Cliff Asness has maintained this position in GLUE for several quarters, showing initial confidence in the investment. Largest addition occurred in Q2 2025, adding 1.05 M shares. Largest reduction occurred in Q3 2025, reducing 566,680 shares.
Analysis based on 13F filings available since 2013 Q2
Cliff Asness's Monte Rosa Therapeutics (GLUE) Holding Value Over Time
Track share changes against reported price movement
Quarterly Monte Rosa Therapeutics (GLUE) Trades by Cliff Asness
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | +67,795 | Add 9.45% | 785,057 | $15.68 |
| Q3 2025 | -566,680 | Reduce 44.14% | 717,262 | $7.41 |
| Q2 2025 | +1.05 M | Add 459.36% | 1.28 M | $4.51 |
| Q1 2025 | +229,536 | New Buy | 229,536 | $4.64 |
Cliff Asness's Monte Rosa Therapeutics Investment FAQs
Cliff Asness first purchased Monte Rosa Therapeutics, Inc. (GLUE) in Q1 2025, acquiring 229,536 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness has held Monte Rosa Therapeutics, Inc. (GLUE) for 4 quarters since Q1 2025.
Cliff Asness's largest addition to Monte Rosa Therapeutics, Inc. (GLUE) was in Q2 2025, adding 1,283,942 shares worth $5.79 M.
According to the latest 13F filing for Q4 2025, Cliff Asness's firm, Aqr Capital Management LLC, owns 785,057 shares of Monte Rosa Therapeutics, Inc. (GLUE), valued at approximately $12.31 M.
As of the Q4 2025 filing, Monte Rosa Therapeutics, Inc. (GLUE) represents approximately 0.01% of Cliff Asness's publicly disclosed stock portfolio, making it one of their key holdings.
Cliff Asness's peak holding in Monte Rosa Therapeutics, Inc. (GLUE) was 1,283,942 shares, as reported at the end of Q2 2025.